Alpha Cognition Inc. (OTCQB: ACOGF) is a clinical stage, biopharmaceutical company dedicated to developing treatments for under-served neurodegenerative diseases, such as Alzheimer's Dementia and ALS. CEO Michael McFadden joins us to break down the types of neurodegenerative diseases that are targeted in the company’s programs.